Navigation Links
Processing Fees on ADRs to be Waived for two Months
Date:8/28/2007

NEW YORK, August 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biopharmaceutical company engaged in the acquisition, development and commercialization of therapeutics for the treatment of unmet medical needs, particularly neuropathic pain and hepatitis C, today announced that issuances of American Depositary Receipts, or ADRs, by the Company's depositary bank, The Bank of New York, will be processed free of the customary charges of The Bank of New York from September 3, 2007 through October 31, 2007.

The Bank of New York will issue ADRs representing American Depositary Shares, or ADSs, if shareholders or their broker deposit Ordinary Shares with The Bank of New York's Custodian, either the Tel Aviv office of Bank Hapoalim B.M., or the London office of The Bank of New York. One ADR will represent an ownership interest in ten of XTL's Ordinary Shares.

Interested investors should contact their brokers to discuss the waived fee and should they have any questions, can contact The Bank of New York in either London or New York as follows:

London

Mark Lewis

Vice President

Tel 020.7964.6089

Fax 020.7964.6024

marlewis@bankofny.com

Or

New York

Jason Paltrowitz

Vice President

Tel 212.815.2077

Fax 212.815.3004

jpaltrowitz@bankofny.com

Ron Bentsur, Chief Executive Officer of XTL, commented, "We want to thank The Bank of New York for offering shareholders this free issuance window in conjunction with the planned cancellation of the Company's Ordinary Shares on the Official List of the United Kingdom Listing Authority, subject to shareholder approval at an Extraordinary General Meeting to be held on September 25, 2007."

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development and commercialization of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating continued undisrupted trading of the Company's ADRs on NASDAQ or the future cancellation of the Company's Ordinary Shares on the Official List of the United Kingdom Listing Authority and similar matters, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Risk factors that could adversely affect our operations are identified from time to time in our reports filed with the Securities and Exchange Commission and the London Stock Exchange, including our annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2007. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.xtlbio.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only. This press release is for informational purposes only and is not an offer to by or the solicitation of an offer to sell any securities

Contact:

Ron Bentsur, Chief Executive Officer

Tel: +1-845-267-0707 ext. 225

+972-8-930-4444


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. DNA Removal for Bioprocessing Applications
2. RNAlater Around the World: The Art of Processing Difficult Samples
3. New Tools for Making and Processing Protein Microarrays.
4. CATI signs agreement for food processing technology
5. Metavante completes purchase of check processing firm
6. School districts contract with Lawson for new data processing software
7. Fiserv plans single entry point for loan processing online
8. Fiserv Credit Processing Selects System To Keep Transactions Quick
9. Milwaukee could be wireless in 18 months
10. SGIs Wisconsin branch builds fastest supercomputer yet in four months
11. Technology Investment in the Next 24 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... 20, 2017 , ... G&L Scientific Inc, a leading provider ... ), has announced the opening of new offices in Cambridge, Massachusetts, strengthening and ... This is the latest step in G&L’s expansion of its global clinical consulting ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, Inc. ... focused on the licensing, development and commercialization of innovative ... Best Company in North America ... the award based on the FDA approval of ... tablets), ENTYCE ® (capromorelin oral solution) and NOCITA ...
(Date:1/20/2017)... http://www.Financialbuzz.com - According ... causes of death worldwide. There were 8.2 million cancer ... related deaths increased gradually over time, the death rates ... various cancers continues to drive demand of biological therapies ... Market Insights, Inc. cancer biological therapy market size was USD ...
(Date:1/19/2017)... SHANGHAI , Jan. 19, 2017 /PRNewswire -- ... medical device open-access capability and technology platform, today ... a leading biology focused preclinical drug discovery contract ... Biosciences will become a wholly-owned subsidiary of WuXi, ... core competences and providing greater services. The acquisition ...
Breaking Biology Technology:
(Date:1/12/2017)... PUNE, India , January 12, 2017 A ... 2015 - 2022," projects that the global biometric technology market is expected to generate ... to 2022. Continue Reading ... ...      (Logo: ...
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol Inc. ... Group, Inc., has been named to the elite "Forbes 30 Under ... one of 600 people in 20 fields nationwide to be recognized ... the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
(Date:1/6/2017)... Colo. , Jan. 5, 2017  SomaLogic ... the "Digital Life Alliance" established by iCarbonX, the ... 2015 to build a "Global Digital Health Ecosystem ... on a combination of individual,s biological, behavioral and ... the agreement between the companies, SomaLogic will provide ...
Breaking Biology News(10 mins):